🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

President Jimmy Carter died today at age 100, having lived w/ melanoma that had spread to his brain & liver for >9y. I grew up in GA admiring him, so as an oncologist, I’d like to honor his life by teaching you a bit. #melsm #MedTwitter First, the ⚠️ signs (ABCDE 👇) & pics /1

Looking back on an amazing year at Cleveland Clinic Urology! Our incredible uro-onc team is leading the way in managing localized & advanced #kidneycancer, and research with 🌟 nephrectomy-transplant trial, AI in RCC, microplastics . 🙌

Dr. J. Kaouk is named as Chair of Cleveland Clinic Dept of Urology Congratulations! Cleveland Clinic Cleveland Clinic Urology

Oligometastatic vs oligoprogressive #RCC treatment strategies. Chad Tang, MD MD Anderson Cancer Center and Leslie Ballas Cedars-Sinai dive into the role of SBRT for #mRCC 🔹 Oligometastatic RCC: SBRT can delay the need for systemic therapy. 🔹 Oligoprogressive RCC: SBRT may extend the benefit

So very excited to welcome this class of rockstars to Cleveland Clinic! Cleveland Clinic Urology Dr. J. Kaouk

Ouch…yes.

Honored to have served on the Cleveland Clinic Urology chair search committee with Drs. Matt Walsh, Sandra Hong Med Peds Hospitalist Jane K Nguyen MD PhD Moshe Ornstein MD. Many thanks to Sue Keough and Michael Palinchik for the heavy lift, and congrats to Dr. Jihad Kaouk on becoming the urology chair.

TALAPR02 looks at Talazoparib/enza vs enza in 1st line CRPC . It has significant OS in ITT HR=0.796. It’s current used in HRR deficient. Subset analysis and wider data still supports the HRR biomarker OS (HRR deficient HR -0.54, HRR non-defficent/NA 0.87), but ITT OS is +ve #GU25

These are the 2 key slides from the #Talapro2 presentation @asco #GU25 Where HR crosses 1.0 in pts w/no known HRR mutation status & Gd3 toxicity difference of 75% vs 45% I think there is still much to discussion to be had of value of #PARP +#ARPI in unselected #ProstateCancer

Can treatment breaks improve outcomes for patients with metastatic renal cell carcinoma? Moshe Ornstein MD discusses the evolution of mRCC therapies & intermittent treatment on this week’s episode of the Cleveland Clinic MD Cancer Advances podcast #CleClinicCancer cle.clinic/40XwsYv

Long waited review on Recent Developments in the management of Renal Cell Cancer by Rana McKay, MD, FASCO JCO Oncology Practice OncoAlert ascopubs.org/doi/pdf/10.120…

1/7 🚨 Newly published JAMA Oncology! Deep dive into strategies for RCC patients progressing on ICIs 🚨 A comprehensive review on the latest data and emerging approaches. Read here: 🧵👇jamanetwork.com/journals/jamao… #RCC #Immunotherapy #JAMAOncology

From Challenges to Cures: Improving Outcomes in Patients With Renal Cell Carcinoma | JCO Oncology Practice ascopubs.org/doi/10.1200/OP…

Hot panel discussion about #ICPI and kidney toxicity #CCNephupdate25 ⁦Cleveland Clinic Kidney Medicine⁩ ⁦Ali Mehdi⁩ ⁦Corey Cavanaugh DO⁩ ⁦Moshe Ornstein MD⁩

🌟How to Optimize Patient Selection in Perioperative RCC Therapy🌟 Insights from Guillermo de Velasco #IKCSEU2025 Kidney Cancer OncoAlert GU Oncology Now @UroToday 🟠 Neoadjuvant: may downstage, treat micromets, ↑compliance 🟠 Adjuvant: DFS/OS benefit in selected pts (KN-564),

Ab#4516 ASCO #ASCO25 by Tian Zhang, MD, MHS 👉bit.ly/4k7p5Wv👉Alliance for Clinical Trials in Oncology Ph 3 PDIGREE trial 👉 ipi-nivo induction (f/ued by nivo, cabo or nivo-cabo in mccRCC #kidneycancer 👉Initial outcomes with induction ipi-nivo👇Toni Choueiri, MD OncoAlert UroToday.com @KidneyCAN

Special thanks to clinical research teams at our site Cleveland Clinic MD & all sites 🌏 for their diligence in ensuring compliance with PROs & data entry. Amanda Nizam, MD Christopher Wee, MD Moshe Ornstein MD Tim Gilligan Case Comp Cancer Ctr

Just three days until KCRS 2025! We’re getting ready to welcome researchers, clinicians, advocates, and patients from around the world to explore the future of #KidneyCancer research. #KCRS25 #AcceleratingCures

The KCRS 2025 Abstract Book is now live! Explore cutting-edge #KidneyCancer research from investigators across the globe. We’re proud to showcase the work that’s driving real progress for patients and families. Check it out! kcrs.kidneycan.org #KCRS25 #AcceleratingCures

Hot off the presses! Tips from the editorial board Journal of Clinical Oncology ASCO on what we're looking for in narrative medicine or poetry pieces for the Journal of Clinical Oncology! The Art of the Art of Oncology | Stephanie Graff, MD, FACP, FASCO Sylvester Comprehensive Cancer Center UMiami Health System ascopubs.org/doi/10.1200/JC…